Log In
Print this Print this

intravenous CBL0137

  Manage Alerts
Collapse Summary General Information
Company Cleveland BioLabs Inc.
DescriptionNext-generation Curaxin anticancer compound which targets p53, NF-kappa B (NF-kB) and heat shock transcription factor 1 (HSF1)
Molecular Target p53 ; Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors and refractory lymphoma; Treat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today